Aurinia Pharmaceuticals Inc. (AUPH) · Oct 30, 2026 · Earnings
In line — Revenue $83.7M vs ~$83.6M consensus; diluted EPS $0.23 vs ~$0.22
Aurinia’s Q3 earnings were broadly in line, while stronger LUPKYNIS sales support a higher 2026 revenue outlook.
Aurinia is a commercial-stage autoimmune company using LUPKYNIS to expand treatment of lupus nephritis while building aritinercept as its next pipeline asset; the latest public filing described LUPKYNIS sales growth and aritinercept development across multiple indications.
The quarter landed broadly where the market expected. Third-quarter revenue of $83.7 million was essentially in line with the published consensus of roughly $83.6 million, while diluted EPS of $0.23 was modestly above the roughly $0.22 estimate. That is a clean execution quarter, not a material earnings surprise.
| Q3 2026 | Q3 2025 | Consensus | |
|---|---|---|---|
| Total revenue (Financial Highlights) | $83.7M (+13.9%) | $73.5M | ~$83.6M |
| LUPKYNIS sales (Financial Highlights) | $79.4M (+12.4%) | $70.6M | |
| Diluted EPS (Financial Highlights) | $0.23 | $0.23 | ~$0.22 |
| Operating cash flow, nine months (Cash Flow statement) | $131.5M (+46.1%) | $90.0M | |
| 2026 total revenue guidance (Guidance) | $325M–$330M | $315M–$325M prior |
LUPKYNIS remains the engine, with growth holding up rather than accelerating sharply. Product sales rose 12% year over year to $79.4 million, and nine-month sales reached $232.4 million. The company is still gaining lupus-nephritis penetration, but the quarter's growth rate was slower than the 19% reported in the second quarter, so the main takeaway is durability rather than a fresh step-change.
The meaningful upside is the raised revenue outlook. Aurinia lifted 2026 total revenue guidance to $325 million–$330 million from $315 million–$325 million, raising the midpoint by $7.5 million. It also narrowed product-sales guidance to $310 million–$315 million from $305 million–$315 million: the top end did not move, but the bottom end rose, showing greater confidence in the commercial base rather than a dramatic acceleration.
The balance sheet gives Aurinia room to keep funding the pipeline and returning capital. Cash, cash equivalents, restricted cash and investments totaled $486.9 million at quarter-end, while operating cash flow reached $131.5 million through nine months. That supports the newly initiated PRESERVE Phase 4 combination study and aritinercept development, although the filing gives no efficacy data yet; these programs remain investment stories, not validated growth drivers.
Bottom line: This was an in-line quarter with a modestly better outlook, not a major earnings beat. The business story is improving incrementally: LUPKYNIS growth remains dependable, cash generation is strong, and higher revenue guidance makes the setup modestly better than before, while the pipeline still awaits clinical proof.
Q4 earnings and full-year results, early 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!